Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
RESEARCH TOOLSreports
Day One Biopharmaceuticals (DAWN) Stock Price & Analysis
173 Followers
DAWN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.67 - $18.07
Previous Close$16.17
Volume421.57K
Average Volume (3M)1.08M
Market Cap
$1.41B
Enterprise Value$1.01B
Total Cash (Recent Filing)$405.54M
Total Debt (Recent Filing)$514.00K
Price to Earnings (P/E)-6.5
Beta-0.59
Next Earnings
Aug 06, 2024EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.49
Shares Outstanding87,389,859
10 Day Avg. Volume721,370
30 Day Avg. Volume1,082,832
Standard Deviation0.35
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)4.08
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue276.26
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.94
Forecast
1Y Price Target
$41.67Price Target Upside157.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Day One Biopharmaceuticals News
PremiumCompany Announcements
Day One Biopharmaceuticals Unveils Updated Corporate Presentation
Bulls Say, Bears Say
Bulls Say
Financial StabilityWith a strong cash position and no debt, Day One Biopharmaceuticals is financially equipped to support operations and the continued commercialization of Ojemda into 2026.
Product LaunchDay One Biopharmaceuticals has begun generating revenue with the first prescriptions of Ojemda in the U.S., indicating an official product launch and the start of sales.
Regulatory MilestoneDay One initiated the process for regulatory approval of Ojemda in Europe, potentially opening up a new and significant market for the drug.
Bears Say
Drug Utilization ConcernsGrowth impact occurred in 15% of patients, and this adverse event could affect the drug's utilization if the incidence rate increases in the real-world setting.
Financial Performance And ProjectionsAnalyst has lowered the initial peak penetration estimate from 80% to 60% and reduced the price target to $40 from $50, reflecting updated sales projections.
Market Dynamics And AdoptionThe initial uptake of Ojemda may be slow due to the unique market dynamics for pLGG, and approximately 90% of the total addressable market is already using existing treatment options.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $9.67 and its highest was $18.07 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Currently, no data Available
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 78 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on May 06, 2024. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.663 by -$0.057.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -$0.75.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 87,389,860 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.663. Following the earnings report the stock price went up 2.892%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Among the largest hedge funds holding Day One Biopharmaceuticals’s share is RA Capital Management. It holds Day One Biopharmaceuticals’s shares valued at 114M.
---
Day One Biopharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.67 (157.70% Upside)
$41.67 (157.70% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 518.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.59%
12-Months-Change
Fundamentals
Return on Equity
-69.97%
Trailing 12-Months
Asset Growth
0.95%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
---
DAWN Stock 12 Month Forecast
Average Price Target
$41.67
▲(157.70% Upside)
Technical Analysis
Sonoma Pharmaceuticals
―
Guardion Health Sciences
―
Helius Medical Technologies
―
Mersana Therapeutics
―
Best Analysts Covering DAWN
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+3.93%
reiterated a buy rating 13 days ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +3.93% per trade.
---